Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06203210 · ClinicalTrials.gov registry record · Phase 3
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
A Phase 3 study of Small-cell Lung Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT06203210 is a Phase 3 study of Small-cell Lung Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 540 participants, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (140% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06203210, a Phase 3 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Conditions Studied
Interventions
- DRUG Topotecan
- DRUG Lurbinectedin
- DRUG Ifinatamab deruxtecan
- DRUG Amrubicin
Study Locations (20)
California
- Clinical Research Providence Medical Foundation - Fullerton
- UCLA Hematology-Oncology - Los Angeles
- UCSF Mission Bay Mission Hall - San Francisco
Florida
- University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center - Miami
- AdventHealth Orlando, Cancer Institute - Orlando
- H. Lee Moffitt Cancer Center and Research Institute, Inc - Tampa
Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
- John Hopkins School of Medicine - Baltimore
New Jersey
- Astera Cancer Care - East Brunswick
- Meridian Health Systems - Neptune City
New York
- Clinical Research Alliance, Inc - Lake Success
- New York University Cancer Center - Laura and Isaac - New York
Arkansas
- Highlands Oncology Group - Springdale
Illinois
- Rush MD Anderson Cancer Center - Chicago
Kentucky
- Baptist Health Lexington - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2029-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06203210
The ClinicalTrials.gov registry entry for NCT06203210 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 225-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (140% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Topotecan is the first listed.
NCT06203210 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06203210 about?
NCT06203210 is a clinical study titled "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer". This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
What is the current status of trial NCT06203210?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2024-05-21. Estimated completion is 2029-02-22.
What conditions does trial NCT06203210 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT06203210?
The interventions under investigation include: Topotecan (DRUG), Lurbinectedin (DRUG), Ifinatamab deruxtecan (DRUG), Amrubicin (DRUG).
Who is sponsoring clinical trial NCT06203210?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06203210 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.